Surgery and Surgery Approach Affect Survival of Patients With Stage I-IIA Small-Cell Lung Cancer: A Study Based SEER Database by Propensity Score Matching Analysis
Overview
Authors
Affiliations
Purpose: The purpose of this study was to observe the significance of surgery and its approach in stage I-IIA (according to 8th American Joint Committee on Cancer Staging Manual) small-cell lung cancer (SCLC) using the Surveillance, Epidemiology, and End Results (SEER) database.
Patients And Methods: A total of 1,421 patients from ages 31 to 93 years who were diagnosed with stage I-IIA SCLC in the SEER database from 2010 to 2015 were analyzed. The 1:1 propensity score matching analysis was used to minimize the effect of selection bias, and 355 pairs of patients' data was performed subsequent statistical analysis. K-M analysis and a Cox proportional hazards model were used to observe the role of surgery and other clinical features in the patients' prognoses on cancer-specific survival (CSS).
Results: Overall, within the whole cohort, the 3- and 5-year CSS rates were 41.0 and 34.0%, respectively. In a Cox regression that adjusted for other clinical features, patients were more likely to benefit from the surgery [hazard ratio (HR) 0.292, 95% confidence interval (CI) 0.237-0.361, < 0.001]. Unadjusted 5-year cancer-specific survival among those with surgery was 55.0%, compared with 23.0% among those without surgery. In the propensity scored-matched dataset, however, 5-year CSS among those with surgery was 54.0%, compared with 17.0% among those without surgery (HR 0.380, 95%CI 0.315-0.457, < 0.001). In patients who received surgery, cases with lobectomy had a better 5-year CSS than those without lobectomy (65.0 vs. 39.0%). The lobectomy might be a protective factor for patients who underwent resection in CSS (HR 0.433, 95%CI 0.310-0.604, < 0.001).
Conclusions: We suggested that the surgery and lobectomy were the independent prognostic as well as the protective factors in stage I-IIA SCLC patients. We recommended that patients with no surgical contraindications receive surgery, preferably, lobectomy.
Jiang H, Xie W, Li X, Wang H, Yu W, Chen X J Cardiothorac Surg. 2023; 18(1):216.
PMID: 37408065 PMC: 10324150. DOI: 10.1186/s13019-023-02314-1.
Excellent survival of pathological N0 small cell lung cancer patients following surgery.
Fu Z, Li D, Deng C, Zhang J, Bai J, Li Y Eur J Med Res. 2023; 28(1):91.
PMID: 36810128 PMC: 9942372. DOI: 10.1186/s40001-023-01044-3.
Advances in Intraoperative Flow Cytometry.
Figueiredo M, Alexiou G, Vartholomatos G, Rehder R Int J Mol Sci. 2022; 23(21).
PMID: 36362215 PMC: 9655491. DOI: 10.3390/ijms232113430.
Brascia D, Marulli G Curr Treat Options Oncol. 2022; 23(12):1645-1663.
PMID: 36269459 PMC: 9768012. DOI: 10.1007/s11864-022-01026-3.
Jin K, Liu X, Guo Y, Wu C, Dai J, Li J Transl Lung Cancer Res. 2022; 11(9):1951-1960.
PMID: 36248336 PMC: 9554686. DOI: 10.21037/tlcr-22-616.